| Literature DB >> 36069352 |
Rune B Strandby1, Niels H Secher2, Rikard Ambrus1, Jens P Gøtze3, Amalie Henriksen1, Carl C Kitchen2, Michael P Achiam1, Lars B Svendsen1.
Abstract
BACKGROUND: A reduced central blood volume is reflected by a decrease in mid-regional plasma pro-atrial natriuretic peptide (MR-proANP), a stable precursor of ANP, and a volume deficit may also be assessed by the stroke volume (SV) response to head-down tilt (HDT). We determined plasma MR-proANP during major abdominal procedures and evaluated whether the patients were volume responsive by the end of the surgery, taking the fluid balance and the crystalloid/colloid ratio into account.Entities:
Keywords: colloids; crystalloid solutions; fluid therapy; human; mid-regional pro-atrial natriuretic peptide; operative; postoperative complications; stroke volume; surgical procedures
Mesh:
Substances:
Year: 2022 PMID: 36069352 PMCID: PMC9543860 DOI: 10.1111/aas.14126
Source DB: PubMed Journal: Acta Anaesthesiol Scand ISSN: 0001-5172 Impact factor: 2.274
FIGURE 1Patient flow chart
Baseline characteristics
| Baseline characteristics | Liver | Pancreas | Gastroesophageal | All patients |
|---|---|---|---|---|
| No. of patients | 25 | 25 | 38 | 88 |
| Age, years | 63 (±9.1) | 66 (±9.8) | 66 (±11.0) | 65 (±10.2) |
| Gender, no. (%) | ||||
| Male | 17 (68.0) | 10 (40.0) | 30 (78.9) | 65 (10.2) |
| BMI, kg cm2 | 26.4 (±4.0) | 23.8 (±4.1) | 26.1 (±4.4) | 25.5 (±4.3) |
| Smoking, no. (%) | ||||
| No | 9 (36.0) | 9 (36.0) | 7 (18.4) | 25 (28.4) |
| Earlier use | 8 (32.0) | 2 (8.0) | 20 (52.6) | 30 (34.1) |
| Active | 7 (4.0) | 14 (56.0) | 11 (28.9) | 32 (36.4) |
| Missing | 1 (4.0) | 0 (0.0) | 0 (0.0) | 1 (1.1) |
| Alcohol, no (%) | ||||
| None | 5 (20.0) | 7 (28.0) | 9 (23.7) | 21 (23.9) |
| Yes, not abuse | 18 (72.0) | 14 (56.0) | 22 (57.9) | 54 (61.4) |
| Yes, abuse | 1 (4.0) | 4 (16.0) | 7 (18.4) | 12 (13.6) |
| Missing | 1 (4.0) | 0 (0.0) | 0 (0.0) | 1 (1.1) |
| ASA, no. (%) | ||||
| 1 | 5 (20.0) | 4 (16.0) | 7 (18.4) | 16 (18.2) |
| 2 | 11 (44.0) | 14 (56.0) | 22 (57.9) | 47 (53.4) |
| 3 | 9 (36.0) | 6 (24.0) | 8 (21.1) | 23 (26.1) |
| 4 | 0 (0.0) | 1 (4.0) | 0 (0.0) | 1 (1.1) |
| Missing | 0 (0.0) | 0 (0.0) | 1 (2.6) | 1 (1.1) |
Note: Values are mean (±SD) or frequency (%).
Abbreviations: ASA, American Society of Anesthesiologists classification; BMI, body mass index.
FIGURE 2Change in plasma MR‐proANP from start to end of surgery according to type of procedure. Values are mean ± SD. *Different from the baseline value, p = .004. GEJ, gastroesophageal; MR‐proANP, mid‐regional pro‐atrial natriuretic peptide
FIGURE 3Change in plasma MR‐proANP in relation to the perioperative fluid balance for patients undergoing gastroesophageal resection. Regression line with 95% CI is shown (n = 38). The horizontal broken line indicates no change in mid‐regional plasma pro‐atrial natriuretic peptide (MR‐proANP)
Fluid input/output, vasopressor treatment, and intraoperative variables
| Intraoperative characteristics | Liver ( | Pancreas ( | Gastroesophageal ( | All patients ( |
|---|---|---|---|---|
| Duration of procedure, min | 184 (±67) | 281 (±52) | 231 (±60) | 232 (±70) |
| MAP, mean, mmHg | 68 (±7) | 65 (±4) | 66 (±6) | 66 (±6) |
| HR, mean, beats min−1 | 65 (±7) | 69 (±12) | 67 (±10) | 67 (±10) |
| Intraoperative hypotension, min | 38 (±21) | 49 (±35) | 75 (±48) | 57 (±41) |
| LR, ml | 1301 (±544) | 1063 (±212) | 1810 (±396) | 1453 (±517) |
| HA 5%, ml | 680 (±640) | 1175 (±445) | 628 (±432) | 796 (±552) |
| Blood products, ml | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| Total fluid administration, ml | 1800 (1200–3000) | 2045 (1843–2809) | 2350 (2048–2949) | 2200 (1776–2877) |
| Blood loss, ml | 885 (±632) | 1289 (±1168) | 672 (±428) | 906 (±791) |
| Urine output, ml | 611 (±464) | 779 (±491) | 424 (±235) | 577 (±414) |
| Total fluid loss, ml | 1497 (±865) | 2068 (±1300) | 1095 (±566) | 1484 (±983) |
| Fluid balance, ml | 513 (±381) | 385 (±478) | 1389 (±452) | 854 (±641) |
| Noradrenalin infusion | ||||
| No. of patients, μg kg−1 min−1 |
0.000 (0.000–0.026) |
0.043 (0.020–0.068) |
0.000 (0.000–0.000) |
0.000 (0.000–0.028) |
| Phenylephrine infusion | ||||
| No of patients, mg min−1 |
0.000 (0.000–0.026) |
0.000 (0.000–0.000) |
0.004 (0.000–0.014) |
0.00 (0.00–0.0053) |
| Phenylephrine boli | ||||
| No of patients, mg |
0.10 (0.00–0.30) |
0.05 (0.00–0.20) |
0.00 (0.00–0.01) |
0.00 (0.00–0.01) |
| Ephedrin boli | ||||
| No of patients, mg |
15 (5–28) |
10 (10–19) |
10 (10–25) |
10 (10–25) |
Note: Values are mean (±SD) or median (interquartile range). Intraoperative hypotension was defined as systolic pressure <90 mmHg or MAP <60 mmHg.
Abbreviations: fluid balance = fluid administration – fluid loss; HA 5%, human albumin 5%; HR, heart rate; LR, lactated Ringer's solution; MAP, mean arterial pressure.
Volume responsiveness evaluated by head‐down tilt by the end of surgery
| Responders (gastroesophageal, | Non‐responders (pancreas, | Non‐responders (liver, | Non‐responders (gastroesophageal, | |||||
|---|---|---|---|---|---|---|---|---|
| Baseline 0◦ | HDT 10◦ | Baseline 0◦ | HDT 10◦ | Baseline 0◦ | HDT 10◦ | Baseline 0◦ | HDT 10◦ | |
| SV, ml | 59 (±10.2) | 68 (±10.7) | 72 (±13.9) | 67 (±13.0) | 76 (±17.1) | 71 (±14.6) | 73 (±15.2) | 69 (±15.1) |
| ScvO2, % | 71.8 (±8.8) | 74.8 (±6.9) | 78.8 (±4.1) | 81 (±4.3) | 77.1 (±5.4) | 77.9 (±5.3) | 74 (±6.6) | 75.7 (±5.9) |
| CO, l min−1 | 4.6 (±1.0) | 5.1 (±1.3) | 4.7 (±1.4) | 4.5 (±1.4) | 4.9 (±0.9) | 4.5 (±1.0) | 4.6 (±1.5) | 4.4 (±1.4) |
Note: The values are mean (±SD). An increase by >10% in SV in response to head‐down tilt was taken to indicate fluid responsiveness.
Abbreviations: CO, cardiac output; HDT, head‐down tilt; ScvO2, mixed central venous saturation; SV, stroke volume.
Different from baseline within groups, p < .05.
Fluid input/output, vasopressor treatment, and postoperative complications according to changes in plasma MR pro‐atrial natriuretic peptide
| Variable | MR‐proANP ≤ −17% | MR‐proANP 0% to −17% | MR‐proANP ≥0% |
|
|---|---|---|---|---|
| Procedure | .794 | |||
| Pancreas, no. (%) | 10 (35) | 6 (20) | 9 (31) | |
| Liver, no. (%) | 8 (28) | 8 (27) | 9 (31) | |
| Gastroesophageal, no. (%) | 11 (37) | 16 (53) | 11 (38) | |
| HA 5%, ml | 563 (±484) | 798 (±492) | 1027 (±595) | .006 |
| LR, ml | 1346 (±456) | 1602 (±587) | 1401 (±473) | .136 |
| Total fluid administration, ml | 2032 (±986) | 2497 (±944) | 2472 (±720) | .094 |
| Blood loss, ml | 803 (±938) | 916 (±770) | 999 (±656) | .653 |
| Urine output, ml | 573 (±417) | 583 (±433) | 576 (±406) | .995 |
| Fluid balance, ml | 657 (±550) | 999 (±697) | 896 (±635) | .115 |
| Phenylephrine boli, mg | 0.13 (±0.17) | 0.33 (±0.34) | 0.30 (±0.28) | .015 |
| Intraoperative hypotension, min | 47 (±44) | 57 (±33) | 67 (±45) | .216 |
| LOS, days | 8.9 (±5.4) | 10.3 (±9.6) | 9.7 (±6.4) | .765 |
| CCI | 16.3 (±16.2) | 16.0 (±17.7) | 24.1 (±19.1) | .147 |
| Minor complications (Dindo‐Clavien Grade 1–3a), no. of patients (%) | 26 (89.7) | 26 (86.7) | 27 (93.1) | .717 |
| Major complications (Dindo‐Clavien Grade 3b–4), no. of patients (%) | 3 (10.3) | 4 (13.3) | 2 (6.9) | .724 |
| Total no. of complications | 80 | 94 | 123 | .135 |
| No. of patients with more than one complication, no. (%) | 13 (44.8) | 18 (60) | 13 (44.8) | .492 |
Note: Values are frequency (%) or mean (±SD).
Abbreviations: CCI, comprehensive complication index; fluid balance = fluid input – fluid output; HA 5%, human albumin 5%; LOS, length of stay; LR, lactated Ringer's solution; MR‐proANP, mid‐regional pro‐atrial natriuretic peptide.
Different from ≤−17%, p < .05.
FIGURE 4Change in plasma MR‐proANP in relation to the administered volume of human albumin 5%. Regression line with 95% CI is shown (n = 88). The horizontal broken line indicates no change in plasma pro‐atrial natriuretic peptide (MR‐proANP)